- Home
- WNEB vs FENC Comparison
WNEB vs FENC Comparison
Compare WNEB & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- FENC
- Stock Information
- Founded
- WNEB 1853
- FENC 1996
- Country
- WNEB United States
- FENC United States
- Employees
- WNEB N/A
- FENC N/A
- Industry
- WNEB Savings Institutions
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WNEB Finance
- FENC Health Care
- Exchange
- WNEB Nasdaq
- FENC Nasdaq
- Market Cap
- WNEB 195.7M
- FENC 222.9M
- IPO Year
- WNEB N/A
- FENC 2001
- Fundamental
- Price
- WNEB $9.79
- FENC $8.64
- Analyst Decision
- WNEB Buy
- FENC Strong Buy
- Analyst Count
- WNEB 3
- FENC 2
- Target Price
- WNEB $9.75
- FENC $13.00
- AVG Volume (30 Days)
- WNEB 204.4K
- FENC 76.0K
- Earning Date
- WNEB 07-22-2025
- FENC 08-12-2025
- Dividend Yield
- WNEB 2.83%
- FENC N/A
- EPS Growth
- WNEB N/A
- FENC N/A
- EPS
- WNEB 0.53
- FENC N/A
- Revenue
- WNEB $72,966,000.00
- FENC $30,912,000.00
- Revenue This Year
- WNEB N/A
- FENC $0.85
- Revenue Next Year
- WNEB $7.94
- FENC $55.16
- P/E Ratio
- WNEB $18.68
- FENC N/A
- Revenue Growth
- WNEB N/A
- FENC N/A
- 52 Week Low
- WNEB $7.25
- FENC $3.96
- 52 Week High
- WNEB $10.09
- FENC $9.30
- Technical
- Relative Strength Index (RSI)
- WNEB 61.62
- FENC 57.86
- Support Level
- WNEB $9.28
- FENC $8.59
- Resistance Level
- WNEB $10.01
- FENC $9.30
- Average True Range (ATR)
- WNEB 0.25
- FENC 0.36
- MACD
- WNEB 0.05
- FENC -0.01
- Stochastic Oscillator
- WNEB 87.50
- FENC 55.31
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.